Phase I Safety Study of DMXAA in Refractory Tumors

NCT ID: NCT00856336

Last Updated: 2009-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-05-31
• Study Completion Date: 2004-01-31

Brief Summary

This was a phase I study aimed at identifying safe doses of DMXAA (now known as ASA404) to be used in future combination studies with chemotherapy.

Detailed Description

This was a multi-centre randomized, double blind study to further characterize the effect of DMXAA on QTc interval, ophthalmic safety and pharmacodynamic effects on tumour blood flow.

Patients with refractory tumors were to each undergo six doses of treatment at weekly intervals, receiving each of six doses of DMXAA (300, 600, 1200, 1800, 2400 and 3000 mg/m2)

Conditions

Refractory Tumors

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

DMXAA

DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Evidence of cancer, by histopathology or cytology, which was not amenable to any standard therapy or was refractory to conventional therapy

2. Age ≥ 18 years

3. Life expectancy of at least 12 weeks

4. WHO performance status of 0-2

5. Hematological and biochemical indices at the start of treatment:

1. Hemoglobin at least 9 g/dl

2. Leukocyte count at least 3.0 x 109/l

3. Neutrophils at least 1.5 x 109/l

4. Platelets at least 100 x 109/l

5. Serum Creatinine not higher than140 μmol/l

6. Liver function tests (ALT, AST, ALK PHOS) no higher than thrice the upper limit of the reference range, if no demonstrable liver metastases or no more than 5 x upper limit of the normal range in the presence of liver or bone metastases

7. Absolute QTc interval values of less than 470 ms in females and less than 450 ms in males as assessed by the Investigator

6. Presence of a lesion which was amenable to dynamic MRI

7. Written informed consent and the ability of the patient to co-operate with treatment and follow up

Exclusion Criteria

1. Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks prior to treatment

2. Pregnant or lactating women were excluded

3. Patients who were poor medical risks because of non-malignant systemic disease, as well as those with active uncontrolled infection

4. Current malignancies at other sites

5. Significant history of recreational drug abuse

6. Glucocorticosteroids in doses exceeding those required for physiological replacement within the previous 2 weeks

7. Skin lesions that may prevent long-term ECG acquisition

8. Body mass index above 30 kg/m2

9. Patients who were taking certain medications

10. Patients with clinical evidence of brain metastases

11. Patients with certain cardiac conditions

1. Advancing or unstable ischemic heart disease

2. Pacing devices and/or implantable cardiovertor-defibrillator

3. Significant cardiovascular disease or any unstable cardiovascular disease

4. Non-sustained or sustained atrial and/or ventricular tachyarrhythmias

5. Atrial fibrillation (including paroxysmal atrial fibrillation) or atrial flutter

6. Bundle Branch Block, any stable intra-cardiac conduction abnormality with QRS complex > 120 ms, any unstable intra-cardiac conduction abnormality

7. Sick sinus syndrome, or sinus pauses > 2 seconds

8. Known atrial and/or ventricular ectopic beats > 10/hour

9. Fixed second degree AV block, transient or fixed third degree AV block

10. History of documented ventricular flutter, ventricular fibrillation, Torsade de Pointes tachycardia

11. Patients who had previously received anthracyclines or other known cardiotoxic medication

12. Women with breast implants as these may have interfered with the recording of the ECG

13. Patients with severe electrolyte abnormalities and patients in whom transient electrolyte abnormalities may have been expected during any visit of the study

14. Patients in whom concomitant neurotropic drug therapy was known to change or was likely to change during the course of the study, where such therapy was likely to affect the patients ERG measurement

15. Ophthalmic conditions where in the opinion of the investigator they might affect the recording of the ERG

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Antisoma Research

INDUSTRY

Sponsor Role: lead

Responsible Party

Antisoma Research Limited

Principal Investigators

Mark McKeage

Role: PRINCIPAL_INVESTIGATOR

The University of Auckland

Michael Jameson

Role: PRINCIPAL_INVESTIGATOR

Waikato Hospital

Mark Jeffery

Role: PRINCIPAL_INVESTIGATOR

Christchurch Hospital

References

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res. 2006 Mar 15;12(6):1776-84. doi: 10.1158/1078-0432.CCR-05-1939.

Reference Type: RESULT

PMID: 16551862 (View on PubMed)

Jameson MB, Sharp DM, Sissingh JI, Hogg CR, Thompson PI, McKeage MJ, Jeffery M, Waller S, Acton G, Green C, Baguley BC. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2553-9. doi: 10.1167/iovs.08-2068. Epub 2009 Apr 22.

Reference Type: DERIVED

PMID: 19387077 (View on PubMed)

Other Identifiers

DART

Identifier Type: -

Identifier Source: org_study_id